Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
21 February 2020AmericasRory O'Neill

Gilead fails to have US government patents invalidated

Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis (PrEP) invalidated.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.

More on this story

Americas
Gilead challenges US govt patents on HIV drug Truvada
22 August 2019   Gilead Sciences, the maker of HIV drug Truvada, has asked the US Patent and Trademark Office to review patents granted to the government covering preventative use of the drug.
Americas
Gilead secures new anti-cancer therapy in $4.9bn deal
2 March 2020   Gilead Sciences has agreed a $4.9 billion deal to buy California-based immuno-oncology company Forty Seven.
Americas
US govt argues Gilead’s patent claims are ‘insufficient’
19 May 2020   The US government has urged a Delaware federal court to throw out patent infringement claims from Gilead Sciences over HIV prevention medicines.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers